Clinical Trial Update: Study Evaluating Multiple Ascending Doses Of ATN-103 In Japanese Subjects With Rheumatoid Arthritis [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports results from a Phase 1/2 study evaluating multiple ascending doses of ATN-103 in Japanese patients with rheumatoid arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ATN-103

Snippet

Sponsor: Ablynx, a Sanofi company | Conditions: Rheumatoid Arthritis | Phase 1, Phase 2 | Status: COMPLETED